Literature DB >> 19523017

Evaluation of cost of treatment of drug-related events in a tertiary care public sector hospital in Northern India: a prospective study.

Smita Pattanaik1, Punit Dhamija, Samir Malhotra, Navneet Sharma, Promila Pandhi.   

Abstract

AIMS: Drug related events (DREs) contribute significantly to hospital admissions. These are largely preventable events and require optimum use of the therapeutic agents. The study was conducted to analyze the cost of treatment of DREs. PATIENTS &
METHODS: All visits to medical emergency department of a tertiary care public sector hospital in northern India were recorded in a prospective, non-interventional manner over a period of 4 months. DREs were recognized and were followed up till their stay in the hospital. Data about the cost generating components of direct and indirect costs of treatment of DREs were collected. The projected cost of treatment of the same DREs in a private sector hospital was estimated and compared.
RESULTS: Out of 1833 admissions, 92(5.01%) were due to DREs. Maximum cases were due to non compliance (66%) followed by ADR (28%) and drug overdose (6%). The common DREs leading to ED visits were cerebrovascular accident (19.44%), followed by accelerated hypertension (18.36%) and diabetic ketoacidosis(14.04%). Total cost of management of all the 92 DREs in our hospital was calculated to be INR17,37,339(Euro 30,215). The direct cost was INR1,72,961 (Euro 3008) and the approximate indirect cost was INR15,64,378 (Euro 27,206). The projected cost of management of all the 92 DREs was estimated to be INR63,63,872(Euro 1,01, 676) in a private sector hospital.
CONCLUSION: The study shows that ADEs leading to emergency department visits and hospitalizations constitute a significant economic burden. Training of the patients and the prescribers may lessen the economic burden on the patient as well as the health care system.

Entities:  

Mesh:

Year:  2008        PMID: 19523017      PMCID: PMC2675048          DOI: 10.1111/j.1365-2125.2008.03346.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

Review 1.  Counting the costs of drug-related adverse events.

Authors:  T J White; A Arakelian; J P Rho
Journal:  Pharmacoeconomics       Date:  1999-05       Impact factor: 4.981

Review 2.  The cost of adverse drug reactions.

Authors:  Sophie Gautier; Hélène Bachelet; Régis Bordet; Jacques Caron
Journal:  Expert Opin Pharmacother       Date:  2003-03       Impact factor: 3.889

Review 3.  Pharmacoeconomics of adverse drug reactions.

Authors:  Jonas Lundkvist; Bengt Jönsson
Journal:  Fundam Clin Pharmacol       Date:  2004-06       Impact factor: 2.748

4.  Hospitalisation for adverse events related to drug therapy: incidence, avoidability and costs.

Authors:  J G Dartnell; R P Anderson; V Chohan; K J Galbraith; M E Lyon; P J Nestor; R F Moulds
Journal:  Med J Aust       Date:  1996-06-03       Impact factor: 7.738

5.  Opportunities and responsibilities in pharmaceutical care.

Authors:  C D Hepler; L M Strand
Journal:  Am J Hosp Pharm       Date:  1990-03

6.  A pharmaceutical manufacturer's perspective on reporting adverse drug experiences.

Authors:  J W Sullivan
Journal:  Am J Hosp Pharm       Date:  1990-06

7.  Drug-related problems: their structure and function.

Authors:  L M Strand; P C Morley; R J Cipolle; R Ramsey; G D Lamsam
Journal:  DICP       Date:  1990-11

8.  A cost-analysis of suspected adverse drug reactions in a hospital emergency ward.

Authors:  I Ayani; C Aguirre; G Gutiérrez; A Madariaga; J M Rodríguez-Sasiaín; M J Martínez-Bengoechea
Journal:  Pharmacoepidemiol Drug Saf       Date:  1999-12       Impact factor: 2.890

9.  Adverse drug reaction monitoring in a secondary care hospital in South India.

Authors:  R Arulmani; S D Rajendran; B Suresh
Journal:  Br J Clin Pharmacol       Date:  2007-07-27       Impact factor: 4.335

10.  Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study.

Authors:  K J Patel; M S Kedia; D Bajpai; S S Mehta; N A Kshirsagar; N J Gogtay
Journal:  BMC Clin Pharmacol       Date:  2007-07-28
View more
  8 in total

1.  A Prospective Surveillance of Pharmacovigilance of Psychotropic Medicines in a Developing Country.

Authors:  Jisha Myalil Lucca; Madhan Ramesh; Gurumurthy Parthasarathi; Dushad Ram
Journal:  Psychopharmacol Bull       Date:  2016-03-01

Review 2.  How are the costs of drug-related morbidity measured?: a systematic literature review.

Authors:  Hanna Gyllensten; Anna K Jönsson; Clas Rehnberg; Anders Carlsten
Journal:  Drug Saf       Date:  2012-03-01       Impact factor: 5.606

Review 3.  Methods for assessing the preventability of adverse drug events: a systematic review.

Authors:  Katja Marja Hakkarainen; Karolina Andersson Sundell; Max Petzold; Staffan Hägg
Journal:  Drug Saf       Date:  2012-02-01       Impact factor: 5.606

4.  Sex-based differences in the predisposing factors of overdose: A retrospective study.

Authors:  Sheng-Teck Tan; Chih-Hung Lo; Chen-Hao Liao; Yu-Jang Su
Journal:  Biomed Rep       Date:  2022-04-20

5.  A Retrospective Analysis of Direct Medical Cost and Cost of Drug Therapy in Hospitalized Patients at Private Hospital in Western India.

Authors:  Prakash R Shelat; Shivaprasad Kalakappa Kumbar
Journal:  J Clin Diagn Res       Date:  2015-11-01

6.  Drug-Related Hospital Admissions and Associated Factors among Adults Admitted to Felege Hiwot Comprehensive and Specialized Hospital, North West Ethiopia.

Authors:  Leila Kenzu Kemal; Tigist Goshu Shewaga; Faisel Dula Sema
Journal:  J Environ Public Health       Date:  2022-03-29

7.  Prevalence and predictors of drug-related hospitalisation among patients visiting emergency departments of Addis Ababa city hospitals in Ethiopia: a multicentre prospective observational study.

Authors:  Mulate Belete Demessie; Alemseged Beyene Berha
Journal:  BMJ Open       Date:  2022-03-09       Impact factor: 2.692

8.  Pharmacogenetic typing for oral anti-coagulant response among factor V Leiden mutation carriers.

Authors:  Risha Nahar; Renu Saxena; Roumi Deb; Ishwar C Verma
Journal:  Indian J Hum Genet       Date:  2012-09
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.